Oramed Pharmaceuticals In... (ORMP)
Oramed Pharmaceuticals Inc. (ORMP) Stock Price, Analysis & Data
| Precio de compra | 3.17 |
| Capitalización de mercado | 177.62M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | 174.06M |
| Beta | 1.16 |
| EPS (TTM) | 2.6 |
| Ratio PER (TTM) | 1.64 |
| Adelante PE | -53.38 |
| P/B (TTM) | 0.73 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 12, 2026 |
| Precio de venta | 5.47 |
| Volumen | 162,673 |
| Volumen medio (20D) | 294,750 |
| Abierto | 4.27 |
| Anterior Cerrar | 4.25 |
| Rango del día | 4.23 - 4.46 |
| Rango de 52 semanas | 1.98 - 5.19 |
| analista | n/a |
| Precio objetivo | 6.25 (46.37%) |
| Dividendos | $0.25 (5.86%) |
| Fecha ex dividendo | 16 ene 2026 |
Acerca de ORMP
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporat...
Desempeño financiero
En 2025, los ingresos de Oramed Pharmaceuticals fueron 2M, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron 64.05M, una disminución de -436.04%.
Estados financierosPronóstico del analista
Según las calificaciones de los analistas de 1, la calificación promedio de las acciones de ORMP es "null". El pronóstico del precio de las acciones a 12 meses es 6.25, que es Potencial alcista de 46.37% del último precio.
Previsiones bursátilesSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
3 meses hace · Simply Wall St.
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny StocksThe market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investment...
